Additional file 1 of Assessment of the treating physicians’ first-hand experience with handling and satisfaction of ofatumumab therapy: findings from the PERITIA survey conducted in Europe

Additional file 1. Supplemental material

sj-docx-1-msj-10.1177_13524585221111677 – Supplemental material for Prediction of relapse activity when switching to cladribine for multiple sclerosis

Supplemental material, sj-docx-1-msj-10.1177_13524585221111677 for Prediction of relapse activity when switching to cladribine for multiple sclerosis by Michael Zhong, Anneke van der Walt, Mastura Monif, Suzanne Hodgkinson, Sara Eichau, Tomas Kalincik, Jeannette Lechner-Scott, Katherine Buzzard, Olga Skibina, Vincent Van Pesch, Ernest Butler, Julie Prevost, Marc Girard, Jiwon Oh, Helmut Butzkueven and Vilija Jokubaitis in Multiple Sclerosis Journal</p

Table_1_Consensus on early detection of disease progression in patients with multiple sclerosis.docx

BackgroundEarly identification of the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) can be challenging for clinicians, as diagnostic criteria for SPMS are primarily based on physical disability and a holistic interpretation.ObjectiveTo establish a consensus on patient monitoring to identify promptly disease progression and the most useful clinical and paraclinical variables for early identification of disease progression in MS.MethodsA RAND/UCLA Appropriateness Method was used to establish the level of agreement among a panel of 15 medical experts in MS. Eighty-three items were circulated to the experts for confidential rating of the grade of agreement and recommendation. Consensus was defined when ≥66% agreement or disagreement was achieved.ResultsConsensus was reached in 72 out of 83 items (86.7%). The items addressed frequency of follow-up visits, definition of progression, identification of clinical, cognitive, and radiological assessments as variables of suspected or confirmed SPMS diagnosis, the need for more accurate assessment tools, and the use of promising molecular and imaging biomarkers to predict disease progression and/or diagnose SPMS.ConclusionConsensus achieved on these topics could guide neurologists to identify earlier disease progression and to plan targeted clinical and therapeutic interventions during the earliest stages of SPMS.</p

sj-docx-1-tan-10.1177_17562864231221331 – Supplemental material for Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Supplemental material, sj-docx-1-tan-10.1177_17562864231221331 for Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies by Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horakova, Eva Kubala Havrdova, Anneke Van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, Karthik Bodhinathan and Tim Spelman in Therapeutic Advances in Neurological Disorders</p

sj-docx-1-msj-10.1177_13524585221084577 – Supplemental material for Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

Supplemental material, sj-docx-1-msj-10.1177_13524585221084577 for Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS by Tomas Kalincik, Ilya Kister, Tamar E Bacon, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala-Havrdova, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani, Murat Terzi, Cavit Boz, Francois Grand’Maison, Roberto Bergamaschi, Oliver Gerlach, Maria J Sa, Ludwig Kappos, Elisabetta Cartechini, Jeannette Lechner-Scott, Vincent van Pesch, Vahid Shaygannejad, Franco Granella, Daniele Spitaleri, Gerardo Iuliano, Davide Maimone, Julie Prevost, Aysun Soysal, Recai Turkoglu, Radek Ampapa, Helmut Butzkueven and Gary Cutter in Multiple Sclerosis Journal</p

sj-docx-1-msj-10.1177_13524585231151951 – Supplemental material for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Supplemental material, sj-docx-1-msj-10.1177_13524585231151951 for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis by Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D’hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Triviño, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A Hardy, Danny Decoo, Angel Perez sempere, Deborah Field, Ray Wynford-Thomas, Nick G Cunniffe, Izanne Roos, Charles B Malpas, Alasdair J Coles, Tomas Kalincik and J William L Brown in Multiple Sclerosis Journal</p